Regencor Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Regencor's estimated annual revenue is currently $1.6M per year.(i)
  • Regencor's estimated revenue per employee is $155,000

Employee Data

  • Regencor has 10 Employees.(i)
  • Regencor grew their employee count by 0% last year.

Regencor's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Regencor?

Regencor is a privately held regenerative medicine company targeting heart disease, the #1 cause of death in the United States. We have discovered and patented that the hypoglycosylated variant of a normal circulating human protein, Follistatin-like 1, (FSTL1) drives heart muscle cells within the infarct zone to undergo controlled proliferation, thereby restoring ventricular contractility, reducing scar volume and preventing progression to heart failure. We are developing two sustained release microsphere formulations of our API, recombinant non-glycosylated human FSTL1 - MyoBeads for delivery to acute MI patients via the infarct related artery at the time of percutaneous coronary revascularization, and Q-Beads, a subcutaneous microsphere formulation of FSTL1 for administration to patients with heart failure. Our core mission is to reduce morbidity and mortality from myocardial infarction, and to prevent the progression to heart failure following MI.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M10N/AN/A
#2
$1.7M110%N/A
#3
$0.9M12-20%N/A
#4
$1.9M120%N/A
#5
$1M1330%N/A